Procalcitonin NH2‐terminal cleavage peptide has no mitogenic effect on normal human osteoblast‐like cells

Christian Hassager, Susan K. Bonde, Marlys A. Anderson, H. Rink, Thomas C. Spelsberg, B. Lawrence Riggs

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

The NH2‐terminal cleavage peptide of procalcitonin (N‐proCT) recently was reported to be a bone cell mitogen (Burns DM et al., Proc Natl Acad Sci USA 86:9519–9523, 1989). We have investigated the effect of N‐proCT on the proliferation of normal human cells that have the phenotype of mature osteoblasts (hOB cells). N‐proCT treatment for 24, 48, or 96 h in concentrations from 1 nM to 1 μM did not significantly increase [3H]thymidine uptake (means ranged from ‐19% to 38% of control, no significant differences) in hOB cells (6–10 cell strains per experiment) plated at four different densities. However, the hOB cells responded significantly to treatment with transforming growth factor β (3 ng/ml), bovine insulin (300 μg/ml), or 30% fetal calf serum, which were included in all experiments as positive controls. The [3H]thymidine uptake data were confirmed in a direct cell count experiment tested at 96 h. Thus our data do not support the hypothesis that N‐proCT is a potent mitogen for normal human osteoblasts.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalJournal of Bone and Mineral Research
Volume6
Issue number5
DOIs
StatePublished - May 1991

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Fingerprint

Dive into the research topics of 'Procalcitonin NH<sub>2</sub>‐terminal cleavage peptide has no mitogenic effect on normal human osteoblast‐like cells'. Together they form a unique fingerprint.

Cite this